These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35491829)

  • 21. Evaluation of doravirine-based regimen population target in a large Italian clinical center.
    Farinacci D; Ciccullo A; Lombardi F; Moschese D; D'Angelillo A; Iannone V; Lamanna F; Passerotto RA; Giambenedetto SD
    Antivir Ther; 2021 May; 26(3-5):79-83. PubMed ID: 35485330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
    Orkin C; Squires KE; Molina JM; Sax PE; Wong WW; Sussmann O; Kaplan R; Lupinacci L; Rodgers A; Xu X; Lin G; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C; Martin EA;
    Clin Infect Dis; 2019 Feb; 68(4):535-544. PubMed ID: 30184165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
    Feng M; Wang D; Grobler JA; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2015 Jan; 59(1):590-8. PubMed ID: 25385110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
    Ly JK; Margot NA; MacArthur HL; Hung M; Miller MD; White KL
    Antivir Chem Chemother; 2007; 18(6):307-16. PubMed ID: 18320935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
    Gregson J; Rhee SY; Datir R; Pillay D; Perno CF; Derache A; Shafer RS; Gupta RK
    J Infect Dis; 2020 Sep; 222(7):1108-1116. PubMed ID: 31774913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
    Bulteel N; Bansi-Matharu L; Churchill D; Dunn D; Bibby D; Hill T; Sabin C; Nelson M; ;
    J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
    Cahn P; Sierra Madero J; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Pappa KA; Curtis L; Smith KY; Gartland M; Aboud M; van Wyk J; Wynne B
    AIDS; 2022 Jan; 36(1):39-48. PubMed ID: 34534138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV.
    Sterman FL; Lalezari JP; Kowalczyk UM; Main DW; Grant EM; Caro L; Manning CM; Burke RL
    AIDS; 2023 Jun; 37(7):1057-1064. PubMed ID: 36927740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
    Li S; Ouyang J; Zhao B; An M; Wang L; Ding H; Zhang M; Han X
    BMC Infect Dis; 2020 Feb; 20(1):123. PubMed ID: 32046664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
    Johnson M; Kumar P; Molina JM; Rizzardini G; Cahn P; Bickel M; Mallolas J; Zhou Y; Morais C; Kumar S; Sklar P; Hanna GJ; Hwang C; Greaves W;
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):463-472. PubMed ID: 30985556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
    Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
    Feng M; Sachs NA; Xu M; Grobler J; Blair W; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2241-7. PubMed ID: 26833152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
    Wong A; Goldstein D; Mallolas J; DeJesus E; Johnson M; Molina JM; Pozniak A; Rodgers A; Teal V; Hepler D; Kumar S; Sklar P; Hanna GJ; Hwang C; Badshah C; Teppler H
    J Acquir Immune Defic Syndr; 2019 Dec; 82(4):e47-e49. PubMed ID: 31425317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
    Oliveira M; Brenner BG; Xu H; Ibanescu RI; Mesplède T; Wainberg MA
    J Antimicrob Chemother; 2017 Nov; 72(11):3008-3011. PubMed ID: 28961903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China.
    Chen M; Wu M; Zeng L; Zhang Y; Huobu-Mo M; Li J; Li C; Xiao H
    J Glob Antimicrob Resist; 2023 Mar; 32():98-103. PubMed ID: 36708768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.